Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer

Pancreatic cancer has one of the worst prognoses among all cancers due to the late manifestation of identifiable symptoms and high resistance to chemo- and radiation therapies. In recent years, a cancer development phase termed epithelial-mesenchymal transition (EMT) has gained increasing research f...

Full description

Bibliographic Details
Main Authors: Elaskalani, O., Razak, N., Falasca, Marco, Metharom, Pat
Format: Journal Article
Published: BAISHIDENG PUBLISHING GROUP INC 2017
Online Access:http://hdl.handle.net/20.500.11937/56690
_version_ 1848759914949771264
author Elaskalani, O.
Razak, N.
Falasca, Marco
Metharom, Pat
author_facet Elaskalani, O.
Razak, N.
Falasca, Marco
Metharom, Pat
author_sort Elaskalani, O.
building Curtin Institutional Repository
collection Online Access
description Pancreatic cancer has one of the worst prognoses among all cancers due to the late manifestation of identifiable symptoms and high resistance to chemo- and radiation therapies. In recent years, a cancer development phase termed epithelial-mesenchymal transition (EMT) has gained increasing research focus. The process is implicated in tumour metastasis, and emerging evidence suggests EMT also contributes or induces chemoresistance in several cancers. Nevertheless, the applicability of therapeutic targeting of EMT faces many challenges. In this mini-review, we summarise the evidence supporting the role of EMT in pancreatic cancer progression, focusing particularly on its association with chemoresistance.
first_indexed 2025-11-14T10:07:28Z
format Journal Article
id curtin-20.500.11937-56690
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T10:07:28Z
publishDate 2017
publisher BAISHIDENG PUBLISHING GROUP INC
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-566902018-02-12T05:59:35Z Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer Elaskalani, O. Razak, N. Falasca, Marco Metharom, Pat Pancreatic cancer has one of the worst prognoses among all cancers due to the late manifestation of identifiable symptoms and high resistance to chemo- and radiation therapies. In recent years, a cancer development phase termed epithelial-mesenchymal transition (EMT) has gained increasing research focus. The process is implicated in tumour metastasis, and emerging evidence suggests EMT also contributes or induces chemoresistance in several cancers. Nevertheless, the applicability of therapeutic targeting of EMT faces many challenges. In this mini-review, we summarise the evidence supporting the role of EMT in pancreatic cancer progression, focusing particularly on its association with chemoresistance. 2017 Journal Article http://hdl.handle.net/20.500.11937/56690 10.4251/wjgo.v9.i1.37 http://creativecommons.org/licenses/by-nc/4.0/ BAISHIDENG PUBLISHING GROUP INC fulltext
spellingShingle Elaskalani, O.
Razak, N.
Falasca, Marco
Metharom, Pat
Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer
title Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer
title_full Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer
title_fullStr Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer
title_full_unstemmed Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer
title_short Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer
title_sort epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer
url http://hdl.handle.net/20.500.11937/56690